Content area

|
|

Der er evidens for brug af cannabinoider til symptomatisk behandling af multipel sklerose

Forfatter(e)
Henadzi Basinski1, Henrik Boye Jensen2, 3, 4 & Egon Stenager2, 3 1) Neurologisk Afdeling, Sydvestjysk Sygehus 2) Institut for Regional Sundhedsforskning 3) Sydjysk Skleroseklinik, Sønderborg, Esbjerg, Vejle 4) Neurologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2014;176:V09130552
Reference: 
Ugeskr Læger 2014;176:V09130552
Blad nummer: 
Sidetal: 
956-960
There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis
We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jesper Andreas Evers Palshof | 17/11
9 kommentarer
af Peter Søndergaard | 17/11
1 Kommentar
af Tom Nygaard Kristensen | 16/11
1 Kommentar
af Susanne Udengaard Gydesen | 16/11
6 kommentarer
af Lars Otto Hutters | 16/11
2 kommentarer
af Mette Cathrine Lauridsen | 16/11
2 kommentarer
af Peter Tagmose Thomsen | 09/11
1 Kommentar